Over the past couple of years, "Big Pharma" has largely moved away from psychiatric drug development. This shift has been widely discussed.
But another trend has been happening over the same time period - or so it seems to me. This is the rise ofsmall companies who offer techniques for diagnosing mental illness, or predicting which drugs will work best. Generally (it seems) partnerships between venture capitalists and psychiatry (ex-)researchers, these enterprises might be dubbed "Little Pharma".